Adverse effects of immunotherapy in advanced non-small cell lung cancer and their correlation with efficacy
10.19405/j.cnki.issn1000-1492.2025.04.025
- Author:
Mengjie Tian
1
;
Xinjun Liang
1
Author Information
1. Dept of Abdominal Oncology，Hubei Cancer Hospital，Tongji Medical College， Huazhong University of Science and Technology，Wuhan 430079
- Publication Type:Review
- Keywords:
immune checkpoint inhibitors;
immune-related adverse reactions;
non-small cell lung cancer;
effica- cy;
predictive metrics
- From:
Acta Universitatis Medicinalis Anhui
2025;60(4):755-760
- CountryChina
- Language:Chinese
-
Abstract:
Abstract:Non-small cell lung cancer(NSCLC), the most prevalent type of lung cancer, has a poor prognosis in patients with advanced disease. In recent years, immune checkpoint inhibitors(ICIs) have demonstrated promising efficacy in this disease, while bringing a unique set of immune-related adverse events(irAEs). This article comprehensively explores the multi-systemic irAEs of programmed death protein-1(PD-1)/programmed death protein ligand-1(PD-L1) inhibitors in the treatment of NSCLC, including but not limited to dermatotoxicity, endocrine toxicity,hepatic toxicity and gastrointestinal toxicity. The occurrence of these adverse reactions not only poses a challenge for clinical treatment,but also correlates with treatment efficacy. In addition,the paper discusses biomarkers for predicting the risk of ir AEs,such as gut microbiota,blood biomarkers,etc.,with the aim of providing a potential risk assessment tool for the clinic.
- Full text:2026020417140453737晚期非小细胞肺癌免疫治疗不良反应及其与疗效的相关性_田梦婕.pdf
